tors could help level the playing field for hospitals serving disadvantaged patients. Moreover, policymakers could provide underresourced hospitals with access to quality-improvement assistance or introduce downside risk more slowly for these hospitals. Additionally, creating separate tracks for low-and highvolume hospitals, and hospitals with vastly different clinical capabilities and resources, might persuade lower-volume, less well-resourced, and safety-net hospitals to join future bundled payment programs. 7 Ultimately, if bundled payments are to truly achieve their promise as a broadly viable tool for improving the efficiency of care, then policymakers and health systems leaders must make it easier for a diverse set of acute care hospitals to participate in and excel under bundled payment programs. 
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LESS IS MORE

Analysis of Diagnostic Test Ordering Habits Among Internal Medicine Residents
The Dartmouth Atlas of Health Care sheds light on wide variations in spending for Medicare beneficiaries in the 6 months before their death.
1 That report has led to several efforts to better standardize patient care. High-value care has been defined as the seventh competency, with national efforts to educate physicians and physicians in training about how to deliver higher-quality care, while decreasing the cost of that care.
2 Medical students and residents are particular targets for this effort because of the known "imprinting," or sustained influence, that the training environment has on practice habits during a physician's career.
3
Kahneman and colleagues 4 found that professionals express a much greater-than-expected degree of variability in the outcomes of their work, even when given the same data with which to base their conclusions. We are aware of 2 previous studies that showed a large degree of variability in resident patterns of test ordering. One study 5 analyzed outpatient test ordering in 1987, and another, 6 "practice intensity" in 2015.
Methods | We analyzed electronic diagnostic test orders placed in the inpatient medical record by internal medicine residents at an academic medical center (NewYork-Presbyterian/ Weill Cornell Medical Center). Among 139 internal medicine residents in this study, we compared the aggregate profiles of each resident over the course of academic year (AY) 2016-2017 for the total number of tests each resident ordered and the mean number of tests each resident ordered per patient for whom he or she provided care. The Weill Cornell Medicine institutional review board approved this study and granted an exemption from human participant review because all data were deidentified.
Results | The residents in the New York-Presbyterian (Cornell Campus) internal medicine residency program ordered laboratory tests for 10 707 patients during 13 469 unique patient hospitalizations in AY 2016-2017. During these unique patient hospitalizations, the residents ordered 579 935 laboratory tests and 29 881 radiology tests. The resident who ordered the most laboratory tests (n = 13 604) ordered more than 7 times the tests than the resident who ordered the least (n = 1870) (interquartile range [IQR] , 3509-6148) ( Figure 1 ). The resident who ordered the most tests per unique patient hospitalization ordered 41.2 tests per patient compared with 9.0 tests per patient for the resident who ordered the least (IQR, ), a 4.6-fold difference. The resident who ordered the most radiology tests (n = 826) ordered approximately 8 times the tests than the resident who ordered the least (n = 104) (IQR, and approximately 3 times the tests per unique patient hospitalization (range, 1.6-5.0; IQR, 1.9-2.4) ( Figure 2 ). Linear regression showed an association between postgraduate year (PGY) and the total number of laboratory tests ordered (R 2 = 0.21; slope, −1187) and between PGY and the number of laboratory tests per patient (R 2 = 0.19; slope, −3.2) but demonstrated no such associations for radiology testing (R 2 < 0.01 for both). There was also a strong association between the total number of tests ordered and the mean number of tests per patient for both laboratory orders (R 2 = 0.85; slope, 325) and radiology orders (R 2 = 0.61; slope, 132).
Discussion | This study found that over the course of AY 2016-2017 some residents ordered 7 to 8 times more diagnostic tests than their peers. Even excluding outliers, we observed much more variation in diagnostic test ordering volume than expected given that there were minimal differences in resident schedules among each PGY cohort during the 1-year period. The residents in their first PGY residents tended to order more laboratory tests than the residents in their second or third PGY, Editor's Note page 1721 likely because of a cultural norm in our urban teaching hospital (NewYork-Presbyterian/Weill Cornell Medical Center) where interns are responsible for ordering daily laboratory testing. Curiously, the top 3 residents by laboratory test ordering volume included individuals from each PGY. The most significant limitation of this study is the inability to normalize test ordering frequency for patient acuity. We are also blind to the potential degree to which supervising physicians may directly or indirectly influence test ordering behavior.
Because residents are "imprinted" by their training environment, even small reductions in diagnostic test ordering habits during training could translate to years of higher-value care. Future research should evaluate the reasons for this variability. There was a much greater-thanexpected degree of variability between the residents in terms of the total number of laboratory tests ordered over the course of a year in which their schedules contained roughly the same number and types of rotations. There was a strong, positive linear association between the total number of laboratory tests ordered and the mean number of laboratory tests ordered per unique patient hospitalization (R 2 = 0.85; slope, 325). There is a shift where more upper-level residents are at the higher end of the ordering spectrum, perhaps reflecting their greater involvement in decision making regarding radiology testing. There was no linear association between postgraduate year (PGY) and the total number of radiology tests ordered or the mean number of radiology tests ordered per unique patient hospitalization. There was a positive linear association between the total number of radiology tests ordered and the mean number of radiology tests ordered per patient (R 2 = 0.61; slope, 132).
Letters
The Persistent Problem of Overuse of Diagnostic Testing Among House Staff-Time to Move Forward
I was a second-year medical student at the University of Pennsylvania, Philadelphia, in 1978, and I had the immense good fortune to work with Sankey Williams, MD, and John Eisenberg, MD. They were performing a trial to evaluate the influence of education on reducing house staff use of unnecessary inpatient laboratory testing.
1 The educational intervention had no benefit on house staff ordering behavior, but it had resounding effects on how I came to view routine use of many different types of testing and treatments that I had previously assumed were evidence based. That early research experience led me to carefully question the evidence base for many commonly used tests and procedures: How will the information from this test help me to take better care of my patient? Will it lead to better outcomes? Could I have gotten there without the use of this test? The Research Letter by Geleris et al 2 in this issue of JAMA Internal Medicine brought back my 40-year-old memories of research on the overuse of diagnostic testing by house staff. Clearly, the problem has not gone away. In their study, Geleris et al 2 found that there is tremendous variation in inpatient laboratory test and radiology test ordering among the house staff, an indicator (particularly when outcomes do not differ) of questionable or unnecessary care, and we publish studies like this one to keep the conversation moving forward. Medicine remains largely an apprenticeship. The practice patterns that residents develop are likely to persist throughout their careers. Residency is the perfect time to think clearly and deeply what can be learned from each potential test and to order only those tests that will affect the care of the patient. 
Prohibited Stimulants in Dietary Supplements After Enforcement Action by the US Food and Drug Administration
The US Food and Drug Administration (FDA) is responsible for eliminating adulterated and potentially hazardous dietary supplements from the marketplace. The FDA uses a variety of enforcement actions, including public notices, to remove potentially hazardous ingredients. However, it is not known whether public notices are effective. We explored the effectiveness of the FDA's public notices issued between 2013 and 2016 targeting prohibited sympathomimetic stimulants in supplements. We analyzed supplements purchased in 2014 and the same brands purchased again in 2017 to determine the presence of prohibited stimulants before and after the FDA issued public notices.
Methods | From January 1, 2013, to December 31, 2016, the FDA issued notices regarding 4 prohibited sympathomimetic stimulants: 1,3-dimethylamylamine (1,3-DMAA), 1,3-dimethylbutylamine (DMBA), β-methylphenylethylamine (BMPEA), and methylsynephrine (oxilofrine).
1-4 The FDA notices regarding ingredients in supplements not categorized as sympathomimetic stimulants, such as picamilon, were excluded from the current analysis. We previously analyzed all supplements on sale in 2014 listing Acacia rigidula as an ingredient for the presence of 1 stimulant, BMPEA. 1 For the current study, we purchased the same brands of supplements in 2017. Supplements purchased in 2014 were reanalyzed for 1,3-DMAA, DMBA, and oxilofrine, and supplements purchased in 2017 were analyzed for all 4 prohibited stimulants subject to FDA enforcement action. As previously described, 1 liquid chromatography-quadrupole time-offlight mass spectrometry was used to analyze the supplements, and the presence of each stimulant was confirmed by accurate mass, retention time, isotope pattern, and at least 1 fragment ion in the mass spectra.
Results | Of the 21 brands of supplements analyzed in 2014, a total of 12 brands (57%) were still available for purchase in 2017. The 12 brands that were available in both 2014 and 2017 were included in the current analysis (Table) . In 2013, the FDA issued a public notice about the use of 1,3-DMAA. Of the 12 supplements purchased in 2014, 1,3-DMAA was present in 6 (50%). The FDA issued notices about the use of DMBA and BMPEA in 2015 and oxilofrine in 2016. Of the 12 supplements purchased in 2017, a total of 9 (75%) contained at least 1 of the 4 stimulants subject to FDA notices, and 6 (50%) contained 2 or more. One stimulant, DMBA, was not detected in any supplement purchased in 2014. After the FDA issued a public notice about DMBA in 2015, DMBA was detected in 4 of the 12 supplements (33%) purchased in 2017.
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